Lysosomal storage disorder biotech Gain Therapeutics prices IPO at $11 midpoint

Gain Therapeutics, a preclinical biotech developing small molecule therapies for lysosomal storage disorders, raised $40 million by offering 3.6 million shares at $11, within the range of $10 to $12. At pricing, the company commands a fully diluted market value of $129 million.

Gain Therapeutics is developing novel therapies to treat diseases caused by protein misfolding, with an initial focus on lysosomal storage disorders. The company has identified and filed three patent applications and one provisional patent application for its novel Structurally Targeted Allosteric Regulators (STARs). Gain expects to obtain additional preclinical data and commence IND-enabling studies for lead compound candidates beginning in 2021.

Gain Therapeutics plans to list on the Nasdaq under the symbol GANX. BTIG and Oppenheimer & Co. acted as lead managers on the deal.

The article Lysosomal storage disorder biotech Gain Therapeutics prices IPO at $11 midpoint originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO), Renaissance International ETF (symbol: IPOS), or separately managed institutional accounts may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Latest IPOs Videos

    Nasdaq 2021 Q1 Listings Highlights

    The IPO market remained active in Q1 of 2021 as it followed the continued momentum seen in the second half of last year. Nasdaq hit a record first quarter after it welcomed 275 IPOs that raised $74.4 billion in total proceeds.

    6 days ago

    Renaissance Capital

    Renaissance Capital is the global leader in providing pre-IPO institutional research and management of IPO-focused investment products.

    Learn More